T315I mutations are clustered with advanced phases contrary to other aberrations in CML patients resistant to TKI therapy

MALČÍKOVÁ, Jitka, Tomáš JURČEK, Filip RÁZGA, Dana DVOŘÁKOVÁ, Daniela ŽÁČKOVÁ, Nikos DARZENTAS, Ludmila ŠEBEJOVÁ, Jana ŠMARDOVÁ, Alexandra OLTOVÁ, Lenka JURAČKOVÁ, Martin TRBUŠEK, Michael DOUBEK, Šárka POSPÍŠILOVÁ, Jiří MAYER and Zdeněk RÁČIL. T315I mutations are clustered with advanced phases contrary to other aberrations in CML patients resistant to TKI therapy. In 17th Congress of the European Hematology Association, Amsterdam. 2012. ISSN 0390-6078.

Basic information

• Original name: T315I mutations are clustered with advanced phases contrary to other aberrations in CML patients resistant to TKI therapy
• Authors: MALČÍKOVÁ, Jitka, Tomáš JURČEK, Filip RÁZGA, Dana DVOŘÁKOVÁ, Daniela ŽÁČKOVÁ, Nikos DARZENTAS, Ludmila ŠEBEJOVÁ, Jana ŠMARDOVÁ, Alexandra OLTOVÁ, Lenka JURAČKOVÁ, Martin TRBUŠEK, Michael DOUBEK, Šárka POSPÍŠILOVÁ, Jiří MAYER and Zdeněk RÁČIL.
• Edition: 17th Congress of the European Hematology Association, Amsterdam, 2012.

Other information

• Original language: English
• Type of outcome: Conference abstract
• Field of Study: 30200 3.2 Clinical medicine
• Country of publisher: Italy
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• Impact factor: Impact factor: 5.935
• Organization unit: Central European Institute of Technology
• ISSN: 0390-6078
• Tags: International impact, Reviewed

Abstract

Various mechanisms of resistance to tyrosine kinase inhibitors (TKIs) in chronic myelogenous leukemia (CML) patients were described. Among them, mutations within BCR-ABL1 kinase domain are the most frequently studied, since they affect binding of TKI molecule. However, mechanisms leading to subsequent progression are still not fully elucidated. Inhibition of BCR-ABL1 by imatinib was suggested to induce p53 pathway, therefore, p53 inactivation could possibly influence therapy response. Beside this, mutations in genes involved in myeloid transformation (e.g. ASXL11 and CBL) were identified, and their role in disease progression is under investigation. Aims. We analyzed genomic aberrations and mutations in BCR-ABL1, TP53, ASXL1 and CBL genes in patients with primary or acquired resistance to TKIs therapy.

Links

• CZ.1.07/2.4.00/17.0042, interní kód MU: Name: InterBioNet - Podpora mezinárodní a mezisektorové spolupráce ve výzkumu a vývoji v oblasti věd o živé přírodě

Investor: Ministry of Education, Youth and Sports of the CR, 2.4 Partnership and networks

• ED1.1.00/02.0068, research and development project: Name: CEITEC - central european institute of technology
• EE2.3.20.0045, research and development project: Name: Podpora profesního růstu a mezinárodní integrace výzkumných týmů v oblasti molekulární medicíny
• MSM0021622430, plan (intention): Name: Funkční a molekulární charakteristiky nádorových a normálních kmenových buněk - identifikace cílů pro nová terapeutika a terapeutické strategie

Investor: Ministry of Education, Youth and Sports of the CR, Functional and molecular characteristics of cancer and normal stem cells - identification of targets for novel therapeutics and therapeutic strategies

• MUNI/A/0784/2011, interní kód MU: Name: Nové diagnostické a klinické přístupy v onkologii (Acronym: NoDiKliPO)

Investor: Masaryk University, Category A